Dual Antithrombotic Therapy With Dabigatran vs Triple Therapy With Warfarin After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation With or Without a Proton Pump Inhibitor (A Prospectively Defined Subgroup Analysis in the RE-DUAL PCI Randomized Trial).

被引：0
|
作者：
Nicolau, Jose C. [1 ]
Bhatt, Deepak L. [2 ]
Hohnloser, Stefan H. [3 ]
Kimura, Takeshi [4 ]
Lip, Gregory Y. [5 ]
Meide, Corinna [6 ]
Nordaby, Matias [7 ]
Oldgren, Jonas [8 ,9 ]
Steg, Philippe [10 ]
ten Berg, Jurrien M. [11 ]
Cannon, Christopher [12 ,13 ]
机构：
[1] Univ Sao Paulo, Fac Med, Inst Coracao InCor, Hosp Clin HCFMUSP, Sao Paulo, SP, Brazil
[2] Brigham & Womens Hosp, Boston & Harvard Med Sch, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[3] Goethe Univ Frankfurt, Div Cardiol, Dept Med, Frankfurt, Germany
[4] Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan
[5] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[6] HMS Analyt Software GmbH, Software, Weimar, Lahn, Germany
[7] Boehringer Ingelheim Int GmbH, TA CardioMetab, Ingelheim, Germany
[8] Uppsala Univ, Uppsala Clin Rsch Ctr, Uppsala, Sweden
[9] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[10] Hop Bichat Claude Bernard, Dept Cardiol, AP HP, Paris, France
[11] St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands
[12] Brigham & Womens Hosp, Div Cardiol, Heart & Vasc Ctr, Boston, MA 02115 USA
[13] Harvard Med Sch, Boston, MA 02115 USA
来源：
CIRCULATION | 2018年 / 138卷
关键词：
Antithrombotic therapy; Atrial fibrillation; Coronary artery disease; Dabigatran; Percutaneous coronary intervention (PCI);
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A11775
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial
    Berry, Natalia C.
    Mauri, Laura
    Steg, Philippe Gabriel
    Bhatt, Deepak L.
    Hohnloser, Stefan H.
    Nordaby, Matias
    Miede, Corinna
    Kimura, Takeshi
    Lip, Gregory Y. H.
    Oldgren, Jonas
    ten Berg, Jurrien M.
    Cannon, Christopher P.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (04) : E008349
  • [22] Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention
    Saito, Yuichi
    Kobayashi, Yoshio
    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS, 2020, 35 (01) : 44 - 51
  • [23] Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention
    Yuichi Saito
    Yoshio Kobayashi
    Cardiovascular Intervention and Therapeutics, 2020, 35 : 44 - 51
  • [24] Benefit of Dual versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Stenting: Insights From a Landmark Analysis of RE-DUAL PCI
    Peterson, Benjamin E.
    Bhatt, Deepak L.
    Steg, Philippe Gabriel
    Oldgren, Jonas
    Maeng, Michael
    Zeymer, Uwe
    Halvorsen, Sigrun
    Hohnloser, Stefan H.
    Lip, Gregory Y.
    Kimura, Takeshi
    Nordaby, Matias
    Kleine, Eva
    ten Berg, Jurrien M.
    Cannon, Christopher
    CIRCULATION, 2018, 138
  • [25] Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation The RE-DUAL PCI Trial Subanalysis
    ten Berg, Jurrien M.
    de Veer, Anne
    Oldgren, Jonas
    Steg, Philippe Gabriel
    Zateyshchikov, Dmitry A.
    Jansky, Petr
    Seung, Ki-Bae
    Hohnloser, Stefan H.
    Lip, Gregory Y. H.
    Nordaby, Matias
    Kleine, Eva
    Bhatt, Deepak L.
    Cannon, Christopher P.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (23) : 2331 - 2341
  • [26] Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug?
    Rubboli, Andrea
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 46 : E40 - E41
  • [27] Comparison of the Effect of Age (< 75 Versus ≥75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)
    ten Berg, Jurrien M.
    Steg, Philippe Gabriel
    Bhatt, Deepak L.
    Hohnloser, Stefan H.
    de Veer, Anne
    Nordaby, Matias
    Miede, Corinna
    Kimura, Takeshi
    Lip, Gregory Y. H.
    Oldgren, Jonas
    Cannon, Christopher P.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (05): : 735 - 743
  • [28] Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes
    Maeng, Michael
    Steg, Philippe Gabriel
    Bhatt, Deepak L.
    Hohnloser, Stefan H.
    Nordaby, Matias
    Miede, Corinna
    Kimura, Takeshi
    Lip, Gregory Y. H.
    Oldgren, Jonas
    ten Berg, Jurrien M.
    Cannon, Christopher P.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (23) : 2346 - 2355
  • [29] Comparison of triple antithrombotic therapy and dual antiplatelet therapy for patients with atrial fibrillation after percutaneous coronary stenting
    Fan, Xiaoying
    Zhang, Yao
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 29 (05) : 1769 - 1773
  • [30] Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI
    Hohnloser, Stefan H.
    Steg, Philippe Gabriel
    Oldgren, Jonas
    Nickenig, Georg
    Kiss, Robert G.
    Ongen, Zeki
    Navarro Estrada, Jose L.
    Ophuis, Ton Oude
    Lip, Gregory Y. H.
    Nordaby, Matias
    Kleine, Eva
    ten Berg, Jurrien M.
    Bhatt, Deepak L.
    Cannon, Christopher P.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (16) : 1553 - 1561
12345